Recently, the State Council officially issued the "Twelfth Five-Year Plan for National Strategic Emerging Industries Development" (hereinafter referred to as the "Planning"), and made clear the development path and various supporting policies for various new types of strategic industries including biomedicine.
"Planning" starts from the current development trend of global biopharmaceuticals and the status quo of biopharmaceutical industry development, and points out the direction for China's future biomedical core technology, and clarifies the future development path and policy support orientation.
When the relevant officials interpreted the plan, they said that the country will formulate a series of supporting policies and support measures to support strategic emerging industries. The core competitiveness and development speed of China's biopharmaceuticals are expected to increase further.
The comprehensive promotion of the core technology “Planning†used a large amount of descriptive texts for the planning and supporting measures of biomedicine. From the current core technologies for the development of China's bio-pharmaceutical industry, and the fastest-growing areas in the world, specific development goals and supporting strategies are proposed, and the average annual growth rate of the industry scale has reached over 20%.
In the biopharmaceutical industry, the "Planning" emphasizes the need to improve China's ability to create new drugs, develop biotech drugs, vaccines, and specific diagnostic reagents, advance the research, development, and industrialization of chemical innovation drugs, and increase the development of generic drug technologies and large-scale production levels. The development of modern Chinese medicine; the development of advanced pharmaceutical technology and equipment, the development of new drug development contract research, health management and other new business, and promote the internationalization of biomedical industry.
In terms of specific targets, a number of international drug development platforms, including genetic engineering drugs, new vaccines, antibody drugs, new chemical drugs, and modern Chinese medicine, have been formed, and the level of research and development in pharmaceutical technology and equipment has increased substantially.
In order to ensure the realization of the above objectives, the "Planning" has clearly defined the direction of state support and construction, emphasizing innovation capacity building, improving the R&D platform for drug innovation, and accelerating the implementation of major new drug development, AIDS and viral hepatitis, and other major infectious disease prevention and control technologies. Major projects; promote the industrialization process of genetic engineering drugs and vaccine drugs; optimize industrial structure, improve product quality and standards, and improve policies such as drug registration management, price management, and centralized bidding and procurement.
In the biomedical engineering industry, it is necessary to integrate the advantages of medical, research, and research resources, promote the cross-fusion of new technologies in the fields of medicine, information, and materials, build a biomedical engineering technology innovation system, and upgrade the development capabilities of new biomedical engineering products.
Focusing on the development of key technologies, researching and developing the core components and key technologies and equipment for high-performance clinical diagnostic equipment; implementing innovative development projects for high-performance medical imaging equipment, stimulating the industrialization of new biomedical engineering technologies and new products; focusing on innovation platform construction Depending on its advantages, the company will build a product innovation and technology integration platform with advanced international standards such as high-performance diagnostic and therapeutic equipment, comprehensive monitoring, tissue engineering, intervention and minimally invasive treatment, and regenerative medicine. Promote industrial upgrading and strengthen health service projects and their management capabilities.
Urgently supporting support for the interpretation of the “planningâ€, Zhang Xiaoqiang, deputy director of the National Development and Reform Commission, said in an exchange with netizens that cultivating and developing strategic emerging industries is an important measure for China to maintain stable and rapid economic development, as well as a way to transform economic development. Need to adjust the industrial structure. We should attach importance to mobilizing all forces. In addition to the state’s capital investment, we must pay more attention to the basic role of the market in allocating resources through the guiding role of national fiscal, fiscal, and fiscal funds.
Zhang Xiaoqiang said that at present, the country is developing a guide catalog for strategic emerging industries' key products and services, and at the same time it will study and formulate a catalogue of strategic emerging industries. These two directories are currently soliciting opinions.
At present, biopharmaceuticals are favored for their growth. China's biopharmaceuticals entered a new stage of development after the new medical reform was officially launched. A large number of domestic state-owned pharmaceutical groups and various innovative biopharmaceutical companies have vigorously developed biomedical fields. Drugs, vaccines, genetic engineering drugs, and biotechnology and equipment products in various fields have entered the clinical R&D stage on a large scale.
However, from the perspective of the development of the entire pharmaceutical industry, the current rapid development of the industry still faces many difficulties. For example, pharmaceutical R&D and innovation capabilities are still not strong enough, and key key technologies in some key areas are relatively scarce. At the same time, the market needs for the development of strategic emerging industries need to be further fully initiated. Industry regulations and institutional systems still need to be further improved, and local governments are implementing various national policy organizations. Inconsistent understanding, etc. In addition, the investment and financing environment of the industry needs further improvement.
What needs to be seen, however, is that the government is developing various types of policies and regulations to improve the industry's mechanism and system in view of the difficulties that exist during the transition of the industry, in order to establish a sound competition mechanism, including a series of plans, catalogues, and standards. And special projects. Zhang Xiaoqiang said that the state will also issue a series of supporting measures and implementation opinions (including fiscal and taxation, investment and financing, etc.) to promote the development of strategic emerging industries.
"Planning" starts from the current development trend of global biopharmaceuticals and the status quo of biopharmaceutical industry development, and points out the direction for China's future biomedical core technology, and clarifies the future development path and policy support orientation.
When the relevant officials interpreted the plan, they said that the country will formulate a series of supporting policies and support measures to support strategic emerging industries. The core competitiveness and development speed of China's biopharmaceuticals are expected to increase further.
The comprehensive promotion of the core technology “Planning†used a large amount of descriptive texts for the planning and supporting measures of biomedicine. From the current core technologies for the development of China's bio-pharmaceutical industry, and the fastest-growing areas in the world, specific development goals and supporting strategies are proposed, and the average annual growth rate of the industry scale has reached over 20%.
In the biopharmaceutical industry, the "Planning" emphasizes the need to improve China's ability to create new drugs, develop biotech drugs, vaccines, and specific diagnostic reagents, advance the research, development, and industrialization of chemical innovation drugs, and increase the development of generic drug technologies and large-scale production levels. The development of modern Chinese medicine; the development of advanced pharmaceutical technology and equipment, the development of new drug development contract research, health management and other new business, and promote the internationalization of biomedical industry.
In terms of specific targets, a number of international drug development platforms, including genetic engineering drugs, new vaccines, antibody drugs, new chemical drugs, and modern Chinese medicine, have been formed, and the level of research and development in pharmaceutical technology and equipment has increased substantially.
In order to ensure the realization of the above objectives, the "Planning" has clearly defined the direction of state support and construction, emphasizing innovation capacity building, improving the R&D platform for drug innovation, and accelerating the implementation of major new drug development, AIDS and viral hepatitis, and other major infectious disease prevention and control technologies. Major projects; promote the industrialization process of genetic engineering drugs and vaccine drugs; optimize industrial structure, improve product quality and standards, and improve policies such as drug registration management, price management, and centralized bidding and procurement.
In the biomedical engineering industry, it is necessary to integrate the advantages of medical, research, and research resources, promote the cross-fusion of new technologies in the fields of medicine, information, and materials, build a biomedical engineering technology innovation system, and upgrade the development capabilities of new biomedical engineering products.
Focusing on the development of key technologies, researching and developing the core components and key technologies and equipment for high-performance clinical diagnostic equipment; implementing innovative development projects for high-performance medical imaging equipment, stimulating the industrialization of new biomedical engineering technologies and new products; focusing on innovation platform construction Depending on its advantages, the company will build a product innovation and technology integration platform with advanced international standards such as high-performance diagnostic and therapeutic equipment, comprehensive monitoring, tissue engineering, intervention and minimally invasive treatment, and regenerative medicine. Promote industrial upgrading and strengthen health service projects and their management capabilities.
Urgently supporting support for the interpretation of the “planningâ€, Zhang Xiaoqiang, deputy director of the National Development and Reform Commission, said in an exchange with netizens that cultivating and developing strategic emerging industries is an important measure for China to maintain stable and rapid economic development, as well as a way to transform economic development. Need to adjust the industrial structure. We should attach importance to mobilizing all forces. In addition to the state’s capital investment, we must pay more attention to the basic role of the market in allocating resources through the guiding role of national fiscal, fiscal, and fiscal funds.
Zhang Xiaoqiang said that at present, the country is developing a guide catalog for strategic emerging industries' key products and services, and at the same time it will study and formulate a catalogue of strategic emerging industries. These two directories are currently soliciting opinions.
At present, biopharmaceuticals are favored for their growth. China's biopharmaceuticals entered a new stage of development after the new medical reform was officially launched. A large number of domestic state-owned pharmaceutical groups and various innovative biopharmaceutical companies have vigorously developed biomedical fields. Drugs, vaccines, genetic engineering drugs, and biotechnology and equipment products in various fields have entered the clinical R&D stage on a large scale.
However, from the perspective of the development of the entire pharmaceutical industry, the current rapid development of the industry still faces many difficulties. For example, pharmaceutical R&D and innovation capabilities are still not strong enough, and key key technologies in some key areas are relatively scarce. At the same time, the market needs for the development of strategic emerging industries need to be further fully initiated. Industry regulations and institutional systems still need to be further improved, and local governments are implementing various national policy organizations. Inconsistent understanding, etc. In addition, the investment and financing environment of the industry needs further improvement.
What needs to be seen, however, is that the government is developing various types of policies and regulations to improve the industry's mechanism and system in view of the difficulties that exist during the transition of the industry, in order to establish a sound competition mechanism, including a series of plans, catalogues, and standards. And special projects. Zhang Xiaoqiang said that the state will also issue a series of supporting measures and implementation opinions (including fiscal and taxation, investment and financing, etc.) to promote the development of strategic emerging industries.
We are a professional Chinese manufacturer of Soil Redeposition Material;we supply various products of Soil Conditioner, and can providing product images and basic parameters with each Soil Water Retainer. Such as Humic acid, fulvic acid, brown sauric acid, green sauric acid, black sauric acid and so on. Look forward to your cooperation!
Soil Conditioner,Soil Redeposition,Soil Recuperation,Soil Water Retainer
Xi'an Quanao Biotech Co., Ltd. , https://www.quanaobio.com